[go: up one dir, main page]

CN117126199A - Synthesis method of fluoroRuidexivir - Google Patents

Synthesis method of fluoroRuidexivir Download PDF

Info

Publication number
CN117126199A
CN117126199A CN202310552338.7A CN202310552338A CN117126199A CN 117126199 A CN117126199 A CN 117126199A CN 202310552338 A CN202310552338 A CN 202310552338A CN 117126199 A CN117126199 A CN 117126199A
Authority
CN
China
Prior art keywords
stir
fluoro
minutes
add
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202310552338.7A
Other languages
Chinese (zh)
Other versions
CN117126199B (en
Inventor
严楠
蒋清辉
杨舒
张向梅
邹安茹
章晓炜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangxi Normal University
Original Assignee
Jiangxi Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangxi Normal University filed Critical Jiangxi Normal University
Priority to CN202310552338.7A priority Critical patent/CN117126199B/en
Publication of CN117126199A publication Critical patent/CN117126199A/en
Application granted granted Critical
Publication of CN117126199B publication Critical patent/CN117126199B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention discloses a method for synthesizing fluoroRuidexivir. The method takes fluoro five-membered sugar (2-deoxidization-2-fluoro-3, 5-di-O-benzyl-D-ribonucleotide-gamma-lactone or 2-deoxidization-2-fluoro-3, 5-di-O-benzyl-D-arabinofuranonic acid-gamma-lactone) as an initial raw material, and obtains 2-ethylbutyl ((S) - ((2R, 3R,4R, 5R) -5- (4-aminopyrrolo [2,1-f ] [1,2,4] triazine-7-yl) -5-cyano) -4-fluoro-3-hydroxy tetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) -L-alanine and 2-ethylbutyl ((S) - ((2R, 3R,4S, 5R) -5- (4-aminopyrrolo [2,1-f ] [1,2,4] triazine-7-yl) -5-cyano) -4-fluoro-3-hydroxy tetrahydrofuran-2-phenoxy) phosphoryl) L-two-renin; the synthesis method has the advantages of short route, simple step operation and relatively high yield, and provides a brand new synthesis path for the synthesis or modification design of nucleoside medicines.

Description

一种氟代瑞德西韦合成方法A kind of synthesis method of fluremdesivir

技术领域Technical field

本发明涉及药物合成方法,具体涉及一种氟代瑞德西韦(2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物或2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物)的合成方法,属药物合成技术领域。The invention relates to a drug synthesis method, specifically to a kind of fluoro-remdesivir (2-ethylbutyl((S)-(((2R,3R,4R,5R))-5-(4-aminopyrrolo[ 2,1-f][1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorus Acyl)-L-alanine compound or 2-ethylbutyl ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1 ,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound), belongs to the field of drug synthesis technology.

背景技术Background technique

1950年2-溴-2-氯-1,1,1-三氟乙烷作为吸入麻醉剂,表明氟调节生物活性分子具有潜力(Ostercamp DL,B.R.,Chemical Aspects of General Anesthesia:Part I.FromEther to Halothane1.Journal of Chemical Education 2006,83,1821);1953年,JosefFried和Emily Sabo发现9α-氟氢可的松(如下反应所示)比皮质醇抗炎活性高10倍以上,表明了在药物分子上指定的位置引入氟原子能够改善其药性(Sabo,J.F.a.E.F.,9-α-Fluoroderivatives of cortisone and hydrocortisone.J.Am.Chem.Soc.1954,76,1455);1957年Robert Duschinsky等人合成含氟药物5-氟尿嘧啶(如反应所示),作为抗肿瘤药,通过抑制胸苷酸合成酶显示出高抗癌活性,从而阻止细胞合成胸苷(C.Heidelberger,N.K.C.,P.Danneberg,D.Mooren,L.Griesbach,R.Duschinsky and R.J.Schnitzer,FLUORINATEDPYRIMIDINES,A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS.Nature 1957,179,663)。这两种含氟药物的发现,奠定了氟在生命科学中作用越来越大的基础,截止到In 1950, 2-bromo-2-chloro-1,1,1-trifluoroethane was used as an inhalation anesthetic, indicating the potential of fluorine to modulate biologically active molecules (Ostercamp DL, B.R., Chemical Aspects of General Anesthesia: Part I. From Ether to Halothane1 .Journal of Chemical Education 2006,83,1821); In 1953, Josef Fried and Emily Sabo discovered that 9α-fludrocortisone (shown in the reaction below) has more than 10 times more anti-inflammatory activity than cortisol, indicating that on the drug molecule Introducing fluorine atoms at designated positions can improve its medicinal properties (Sabo, J.F.a.E.F., 9-α-Fluoroderivatives of cortisone and hydrocortisone. J.Am.Chem.Soc. 1954, 76, 1455); In 1957, Robert Duschinsky and others synthesized fluorine-containing drugs. 5-Fluorouracil (as shown in the reaction), as an anti-tumor drug, shows high anti-cancer activity by inhibiting thymidylate synthase, thereby preventing cells from synthesizing thymidine (C. Heidelberger, N.K.C., P. Danneberg, D. Mooren, L. Griesbach, R. Duschinsky and R. J. Schnitzer, FLUORINATED PYRIMIDINES, A NEW CLASS OF TUMOUR-INHIBITORY COMPOUNDS. Nature 1957, 179, 663). The discovery of these two fluorine-containing drugs laid the foundation for the increasing role of fluorine in life sciences.

2020年底,美国食品和药物管理局批准的含氟药物数量的大体趋势是增长的(Johnson,B.M.;Shu,Y.Z.;Zhuo,X.;Meanwell,N.A.,Metabolic and PharmaceuticalAspects of Fluorinated Compounds.J Med Chem 2020,63,6315-6386)、(Yu,Y.;Liu,A.;Dhawan,G.;Mei,H.;Zhang,W.;Izawa,K.;Soloshonok,V.A.;Han,J.,Fluorine-containingpharmaceuticals approved by the FDA in2020:Synthesis and biologicalactivity.Chinese Chemical Letters 2021)。由于氟的特性,药物分子中引入氟,可改变其多方面的性质,所以氟对核苷类药物的改性具有重要的意义。At the end of 2020, the general trend in the number of fluorinated drugs approved by the U.S. Food and Drug Administration is increasing (Johnson, B.M.; Shu, Y.Z.; Zhuo, X.; Meanwell, N.A., Metabolic and Pharmaceutical Aspects of Fluorinated Compounds. J Med Chem 2020 , 63, 6315-6386), (Yu, Y.; Liu, A.; Dhawan, G.; Mei, H.; Zhang, W.; Izawa, K.; Soloshonok, V.A.; Han, J., Fluorine- containingpharmaceuticals approved by the FDA in 2020:Synthesis and biological activity.Chinese Chemical Letters 2021). Due to the characteristics of fluorine, the introduction of fluorine into drug molecules can change its various properties, so fluorine is of great significance to the modification of nucleoside drugs.

发明内容Contents of the invention

针对现有技术存在的缺陷,本发明的目的是在于提供一种氟代瑞德西韦化合物的化学合成方法,该合成方法具有路线短,步骤操作简单,收率相对较高等特点,对核苷类药物的合成或改性的设计提供一条全新的途径。In view of the shortcomings of the existing technology, the purpose of the present invention is to provide a chemical synthesis method of fluoro-remdesivir compounds, which has the characteristics of short route, simple steps and relatively high yield, and is good for nucleosides. The synthesis or modified design of drug-like drugs provides a completely new approach.

为了实现上述技术目的,本发明提供了一种2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,该方法包括以下步骤:In order to achieve the above technical objectives, the present invention provides a 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]Triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-propyl A method for synthesizing amino acid compounds, the method includes the following steps:

1)将2-脱氧-2-氟-3,5-二-O-苄基-D-核糖酸-γ-内酯与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪通过糖碳苷化反应,得到中间体3;1) Combine 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-ribono-γ-lactone and 4-amino-7-bromopyrrolo[2,1-F][1 ,2,4]Triazine obtains intermediate 3 through sugar carbonation reaction;

2)将中间体3与三氟乙酸、三氟甲磺酸三甲基硅酯和三甲基氰硅烷通过氰基化反应,得到中间体4;2) React intermediate 3 with trifluoroacetic acid, trimethylsilyl trifluoromethanesulfonate and trimethylsilyl cyanide through cyanation to obtain intermediate 4;

3)将中间体4通过脱苄基保护基反应,得到中间体5;3) React intermediate 4 through debenzylation protecting group to obtain intermediate 5;

4)将中间体5与2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸通过磷酸化反应,得到2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物;4) Phosphate the intermediate 5 with 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine to obtain 2-ethylbutyl Base ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5- Cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound;

其中,所述2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的结构式如下:Wherein, the 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]tri The structural formula of the azine-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound is as follows:

中间体3、4、5结构依次如下:The structures of intermediates 3, 4, and 5 are as follows:

作为一个优选的方案,所述糖碳苷化反应的过程为:将1,2-双(氯二甲基硅基)乙烷溶液与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪溶液混合,搅拌5~20min,再加入二异丙胺,搅拌3~10min,再放置在-50℃以下低温环境中,搅拌至少20min,再缓慢滴加正丁基锂,搅拌15~60min,再滴加2-脱氧-2-氟-3,5-二-O-苄基-D-核糖酸-γ-内酯溶液,搅拌1~5小时,再加入柠檬酸溶液,升温至0~5℃,搅拌10~30min。更具体的反应过程:在室温下,置换气体后(采用惰性气体置换空气),将1,2-双(氯二甲基硅基)乙烷的四氢呋喃溶液加入到4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪的四氢呋喃溶液中,搅拌5~20min;再加入二异丙胺,搅拌3~10min;放置-78℃低温恒温搅拌器中降温,搅拌至少20min,再缓慢滴正丁基锂,搅拌15~60min;再将2-脱氧-2-氟-3,5-二-O-苄基-D-核糖酸-γ-内酯溶于四氢呋喃中,滴加到体系中,搅拌1~5h,加入1M柠檬酸溶液,升温至0℃,搅拌10~30min。其中,摩尔比1,2-双(氯二甲基硅基)乙烷:4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪:二异丙胺:2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯=0.5~1.5:1.0:0.5~1.5:1.0~3.0。As a preferred option, the process of the glycosidation reaction is: mixing 1,2-bis(chlorodimethylsilyl)ethane solution with 4-amino-7-bromopyrrolo[2,1-F ][1,2,4] Mix the triazine solution, stir for 5 to 20 minutes, then add diisopropylamine, stir for 3 to 10 minutes, then place it in a low temperature environment below -50°C, stir for at least 20 minutes, and then slowly add n-butylamine dropwise base lithium, stir for 15 to 60 minutes, then add 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-ribono-γ-lactone solution dropwise, stir for 1 to 5 hours, and then add lemon acid solution, raise the temperature to 0~5°C, and stir for 10~30 minutes. A more specific reaction process: at room temperature, after replacing the gas (using an inert gas to replace the air), add the tetrahydrofuran solution of 1,2-bis(chlorodimethylsilyl)ethane to 4-amino-7-bromopyrrole Add [2,1-F][1,2,4]triazine to a tetrahydrofuran solution and stir for 5 to 20 minutes; then add diisopropylamine and stir for 3 to 10 minutes; place it in a -78°C low temperature constant temperature stirrer to cool down and stir. For at least 20 minutes, slowly drop n-butyllithium and stir for 15 to 60 minutes; then dissolve 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-ribono-γ-lactone in tetrahydrofuran , add dropwise to the system, stir for 1 to 5 hours, add 1M citric acid solution, raise the temperature to 0°C, and stir for 10 to 30 minutes. Among them, the molar ratio of 1,2-bis(chlorodimethylsilyl)ethane:4-amino-7-bromopyrrolo[2,1-F][1,2,4]triazine:diisopropylamine: 2-Deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranosyl-γ-lactone=0.5~1.5:1.0:0.5~1.5:1.0~3.0.

作为一个优选的方案,所述氰基化反应的过程为:将中间体3溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再加入三氟乙酸,搅拌5~30min,再滴加三氟甲磺酸三甲基硅酯,搅拌10~60min,再加入三甲基氰硅烷,搅拌1~5h。更具体的反应过程:置换气体后,将中间体3溶于二氯甲烷,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,再加入三氟乙酸,搅拌5~30min,滴加三氟甲磺酸三甲基硅酯,搅拌10~60min,再加入三甲基氰硅烷,搅拌1~5h。摩尔比中间体3:三氟乙酸:三氟甲磺酸三甲基硅酯:三甲基氰硅烷=1.0:1.0~5.0:1.0~10.0:1.0~10.0。As a preferred solution, the process of the cyanation reaction is: dissolve intermediate 3 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, then add trifluoroacetic acid, and stir for 5 to 30 minutes. Then add trimethylsilyl trifluoromethanesulfonate dropwise, stir for 10 to 60 minutes, then add trimethylsilyl cyanide, and stir for 1 to 5 hours. A more specific reaction process: After replacing the gas, dissolve intermediate 3 in methylene chloride, place it in a -78°C low-temperature stirrer to cool down, stir for at least 20 minutes, then add trifluoroacetic acid, stir for 5 to 30 minutes, and add trifluoroacetic acid dropwise. Trimethylsilyl methanesulfonate, stir for 10 to 60 minutes, then add trimethylsilyl cyanide, and stir for 1 to 5 hours. Molar ratio of intermediate 3: trifluoroacetic acid: trimethylsilyl trifluoromethanesulfonate: trimethylsilyl cyanide = 1.0: 1.0~5.0: 1.0~10.0: 1.0~10.0.

作为一个优选的方案,所述脱苄基保护基反应的过程为:将中间体4溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再滴加三氯化硼,并升温至-40~-30℃,搅拌1~5h。更具体的反应过程:置换气体后,将中间体4溶于二氯甲烷,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,再滴加三氯化硼,升温至-40℃,搅拌1~5h。其中,摩尔比中间体4:三氯化硼=1.0:1.0~10.0。As a preferred option, the process of the benzyl protecting group reaction is as follows: dissolve intermediate 4 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, then add boron trichloride dropwise, and Raise the temperature to -40~-30℃ and stir for 1~5h. More specific reaction process: After replacing the gas, dissolve intermediate 4 in methylene chloride, place it in a -78°C low-temperature constant temperature stirrer to cool down, stir for at least 20 minutes, then add boron trichloride dropwise, raise the temperature to -40°C, and stir. 1~5h. Among them, the molar ratio of intermediate 4: boron trichloride = 1.0: 1.0 to 10.0.

作为一个优选的方案,所述磷酸化反应的过程为:将中间体5溶于溶剂及2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸溶于溶剂,并放置在冰浴环境中,缓慢滴加二甲基氯化铝,升至室温搅拌5~10d。更具体的反应过程为:置换气体,将中间体5与2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸溶于丙丁,冰浴条件下,缓慢滴加二甲基氯化铝,升至室温搅拌5~10d。As a preferred option, the process of the phosphorylation reaction is: dissolve intermediate 5 in a solvent and 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)- L-alanine is dissolved in the solvent and placed in an ice bath environment. Dimethylaluminum chloride is slowly added dropwise, and the mixture is raised to room temperature and stirred for 5 to 10 days. A more specific reaction process is: replace the gas, dissolve intermediate 5 and 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine in propylbutyl , under ice bath conditions, slowly add dimethylaluminum chloride dropwise, raise to room temperature and stir for 5 to 10 days.

本发明还提供了一种2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,该方法包括以下步骤:The invention also provides a 2-ethylbutyl ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2, Synthesis of 4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound method, which includes the following steps:

1)将2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪通过糖碳苷化反应,得到中间体9;1) Combine 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranosyl-γ-lactone and 4-amino-7-bromopyrrolo[2,1-F] [1,2,4] Triazine obtains intermediate 9 through sugar carbonation reaction;

2)将中间体9与三氟乙酸、三氟甲磺酸三甲基硅酯和三甲基氰硅烷通过氰基化反应,得到中间体4或中间体10;2) React intermediate 9 with trifluoroacetic acid, trimethylsilyl trifluoromethanesulfonate and trimethylsilyl cyanide through cyanation to obtain intermediate 4 or intermediate 10;

3)将中间体10通过脱苄基保护基反应,得到中间体5或中间体11;3) React intermediate 10 through debenzylation protecting group to obtain intermediate 5 or intermediate 11;

4)将中间体11与2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸通过磷酸化反应,得到2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物;4) Phosphate the intermediate 11 with 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine to obtain 2-ethylbutyl Base ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5- Cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound;

其中,in,

所述2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的结构式如下:The 2-ethylbutyl ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine- The structural formula of 7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound is as follows:

中间体9、10、11结构依次如下:The structures of intermediates 9, 10, and 11 are as follows:

作为一个优选的方案,所述糖碳苷化反应的过程为:将1,2-双(氯二甲基硅基)乙烷溶液与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪溶液混合,搅拌5~20min,再加入二异丙胺,搅拌3~10min,再放置在-50℃以下低温环境中,搅拌至少20min,再缓慢滴加正丁基锂,搅拌15~60min,再滴加2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯溶液,搅拌1~5小时,再加入柠檬酸溶液,升温至0~5℃,搅拌10~30min。更具体的反应过程:在室温下,置换气体后(采用惰性气体置换空气),将1,2-双(氯二甲基硅基)乙烷的四氢呋喃溶液加入到4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪的四氢呋喃溶液中,搅拌5~20min;再加入二异丙胺,搅拌3~10min;放置-78℃低温恒温搅拌器中降温,搅拌至少20min,再缓慢滴正丁基锂,搅拌15~60min;再将2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯溶于四氢呋喃中,滴加到体系中,搅拌1~5h,加入1M柠檬酸溶液,升温至0℃,搅拌10~30min。其中,摩尔比1,2-双(氯二甲基硅基)乙烷:4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪:二异丙胺:2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯=0.5~1.5:1.0:0.5~1.5:1.0~3.0。As a preferred option, the process of the glycosidation reaction is: mixing 1,2-bis(chlorodimethylsilyl)ethane solution with 4-amino-7-bromopyrrolo[2,1-F ][1,2,4] Mix the triazine solution, stir for 5 to 20 minutes, then add diisopropylamine, stir for 3 to 10 minutes, then place it in a low temperature environment below -50°C, stir for at least 20 minutes, and then slowly add n-butylamine dropwise base lithium, stir for 15 to 60 minutes, then add dropwise 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranofuranoic acid-γ-lactone solution, stir for 1 to 5 hours, and then Add citric acid solution, raise the temperature to 0~5°C, and stir for 10~30 minutes. A more specific reaction process: at room temperature, after replacing the gas (using an inert gas to replace the air), add the tetrahydrofuran solution of 1,2-bis(chlorodimethylsilyl)ethane to 4-amino-7-bromopyrrole Add [2,1-F][1,2,4]triazine to a tetrahydrofuran solution and stir for 5 to 20 minutes; then add diisopropylamine and stir for 3 to 10 minutes; place it in a -78°C low temperature constant temperature stirrer to cool down and stir. At least 20 minutes, then slowly drop n-butyllithium, and stir for 15 to 60 minutes; then dissolve 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranosyl-γ-lactone in Add tetrahydrofuran dropwise to the system, stir for 1 to 5 hours, add 1M citric acid solution, raise the temperature to 0°C, and stir for 10 to 30 minutes. Among them, the molar ratio of 1,2-bis(chlorodimethylsilyl)ethane:4-amino-7-bromopyrrolo[2,1-F][1,2,4]triazine:diisopropylamine: 2-Deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranosyl-γ-lactone=0.5~1.5:1.0:0.5~1.5:1.0~3.0.

作为一个优选的方案,所述氰基化反应的过程为:将中间体9溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再加入三氟乙酸,搅拌5~30min,再滴加三氟甲磺酸三甲基硅酯,搅拌10~60min,再加入三甲基氰硅烷,搅拌1~5h。更具体的反应过程:置换气体后,将中间体9溶于二氯甲烷,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,再加入三氟乙酸,搅拌5~30min,滴加三氟甲磺酸三甲基硅酯,搅拌10~60min,再加入三甲基氰硅烷,搅拌1~5h。摩尔比中间体9:三氟乙酸:三氟甲磺酸三甲基硅酯:三甲基氰硅烷=1.0:1.0~5.0:1.0~10.0:1.0~10.0。As a preferred solution, the process of the cyanation reaction is: dissolve intermediate 9 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, then add trifluoroacetic acid, and stir for 5 to 30 minutes. Then add trimethylsilyl trifluoromethanesulfonate dropwise, stir for 10 to 60 minutes, then add trimethylsilyl cyanide, and stir for 1 to 5 hours. A more specific reaction process: After replacing the gas, dissolve intermediate 9 in methylene chloride, place it in a -78°C low temperature constant temperature stirrer to cool down, stir for at least 20 minutes, then add trifluoroacetic acid, stir for 5 to 30 minutes, and add trifluoroacetic acid dropwise. Trimethylsilyl methanesulfonate, stir for 10 to 60 minutes, then add trimethylsilyl cyanide, and stir for 1 to 5 hours. Molar ratio of intermediate 9: trifluoroacetic acid: trimethylsilyl trifluoromethanesulfonate: trimethylsilyl cyanide = 1.0: 1.0~5.0: 1.0~10.0: 1.0~10.0.

作为一个优选的方案,所述脱苄基保护基反应的过程为:将中间体10溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再滴加三氯化硼,并升温至-40~-30℃,搅拌1~5h。更具体的反应过程:置换气体后,将中间体10溶于二氯甲烷,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,再滴加三氯化硼,升温至-40℃,搅拌1~5h。其中,摩尔比中间体10:三氯化硼=1.0:1.0~10.0。As a preferred solution, the process of the debenzylation protecting group reaction is: dissolve the intermediate 10 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, then add boron trichloride dropwise, and Raise the temperature to -40~-30℃ and stir for 1~5h. A more specific reaction process: After replacing the gas, dissolve intermediate 10 in methylene chloride, place it in a -78°C low-temperature constant temperature stirrer to cool down, stir for at least 20 minutes, then add boron trichloride dropwise, raise the temperature to -40°C, and stir. 1~5h. Among them, the molar ratio of intermediate 10: boron trichloride = 1.0: 1.0 to 10.0.

作为一个优选的方案,所述磷酸化反应的过程为:将中间体11溶于溶剂及2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸溶于溶剂,并放置在冰浴环境中,缓慢滴加二甲基氯化铝,升至室温搅拌5~10d。更具体的反应过程为:置换气体后,将中间体11与2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸溶于丙丁,冰浴条件下,缓慢滴加二甲基氯化铝,升至室温搅拌5~10d。As a preferred option, the process of the phosphorylation reaction is: dissolve intermediate 11 in a solvent and 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)- L-alanine is dissolved in the solvent and placed in an ice bath environment. Dimethylaluminum chloride is slowly added dropwise, and the mixture is raised to room temperature and stirred for 5 to 10 days. A more specific reaction process is: after replacing the gas, dissolve intermediate 11 and 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine in Protein and D., under ice bath conditions, slowly add dimethylaluminum chloride dropwise, raise to room temperature and stir for 5 to 10 days.

本发明的2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成反应路线如下:2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine) of the present invention The synthesis reaction route of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound is as follows:

具体反应步骤如下:The specific reaction steps are as follows:

(1)在室温下,置换气体,将1,2-双(氯二甲基硅基)乙烷的四氢呋喃溶液加入到4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪(化合物2)的四氢呋喃溶液中,搅拌10min;加入二异丙胺,搅拌5min;放置-78℃低温恒温搅拌器中降温,搅拌至少20min,缓慢滴正丁基锂,搅拌30min;将2-脱氧-2-氟-3,5-二-O-苄基-D-核糖酸-γ-内酯(化合物1)溶于四氢呋喃中,滴加到体系中,搅拌2h;加入1M柠檬酸溶液,升温至0℃,搅拌20min;分离有机相,减压浓缩得到粗产物中间体3,进一步柱层析纯化得到中间体3;其中,摩尔比1,2-双(氯二甲基硅基)乙烷:化合物2:二异丙胺:化合物1=0.5~1.5:1.0:0.5~1.5:1.0~3.0;(1) At room temperature, replace the gas and add the tetrahydrofuran solution of 1,2-bis(chlorodimethylsilyl)ethane to 4-amino-7-bromopyrrolo[2,1-F][1, 2,4] triazine (compound 2) in tetrahydrofuran solution, stir for 10 minutes; add diisopropylamine, stir for 5 minutes; place in a -78°C low temperature constant temperature stirrer to cool down, stir for at least 20 minutes, slowly drop n-butyllithium, and stir for 30 minutes ; Dissolve 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-ribono-γ-lactone (compound 1) in tetrahydrofuran, add dropwise to the system, stir for 2h; add 1M The citric acid solution was heated to 0°C and stirred for 20 minutes; the organic phase was separated, concentrated under reduced pressure to obtain the crude product Intermediate 3, which was further purified by column chromatography to obtain Intermediate 3; where the molar ratio was 1,2-bis(chlorodimethyl Silyl)ethane: Compound 2: Diisopropylamine: Compound 1=0.5~1.5: 1.0: 0.5~1.5: 1.0~3.0;

(2)置换气体,将中间体3溶于二氯甲烷中,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,加入三氟乙酸,搅拌10min,滴加三氟甲磺酸三甲基硅酯,搅拌30min,加入三甲基氰硅烷,搅拌2h。淬灭反应,升温至室温,分离有机相,减压浓缩,硅胶柱层析得到中间体4,其中,摩尔比中间体3:三氟乙酸:三氟甲磺酸三甲基硅酯:三甲基氰硅烷=1.0:1.0~5.0:1.0~10.0:1.0~10.0;(2) Replace the gas, dissolve intermediate 3 in dichloromethane, place it in a -78°C low temperature constant temperature stirrer to cool down, stir for at least 20 minutes, add trifluoroacetic acid, stir for 10 minutes, and add trimethyl trifluoromethanesulfonate dropwise Silyl ester, stir for 30 minutes, add trimethylsilyl cyanide, and stir for 2 hours. Quench the reaction, raise the temperature to room temperature, separate the organic phase, concentrate under reduced pressure, and perform silica gel column chromatography to obtain intermediate 4, in which the molar ratio of intermediate 3: trifluoroacetic acid: trimethylsilyl trifluoromethanesulfonate: trimethyl Silane cyanide=1.0: 1.0~5.0: 1.0~10.0: 1.0~10.0;

(3)置换气体,将中间体4溶于二氯甲烷,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,滴加三氯化硼,升温至-40℃,搅拌2h,降温至-78℃,滴加干燥的甲醇;将干燥的三乙胺溶于干燥的甲醇,然后滴入反应体系中,滴入完毕,升温至室温,减压浓缩,硅胶柱层析得到中间体5,其中,摩尔比中间体4:三氯化硼=1.0:1.0~10.0;(3) Replace the gas, dissolve intermediate 4 in methylene chloride, place it in a -78°C low temperature constant temperature stirrer to cool down, stir for at least 20 minutes, add boron trichloride dropwise, raise the temperature to -40°C, stir for 2 hours, and cool to - At 78°C, dry methanol was added dropwise; dry triethylamine was dissolved in dry methanol, and then dropped into the reaction system. After the dropwise addition was completed, the temperature was raised to room temperature, concentrated under reduced pressure, and silica gel column chromatography was performed to obtain intermediate 5, in which , molar ratio of intermediate 4: boron trichloride = 1.0: 1.0~10.0;

(4)置换气体,将中间体5与光化学纯化合物2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸(化合物6)溶于吡啶中,冰浴条件下,缓慢滴加二甲基氯化铝,升至室温搅拌7d,加入30%L-酒石酸溶液淬灭反应,加入乙酸乙酯稀释,分离有机相,减压浓缩,硅胶柱层析得到化合物7;其中,摩尔比中间体5:化合物6:二甲基氯化铝=1.0:1.0~5.0:0.1~1.0。(4) Replace the gas and combine intermediate 5 with the photochemically pure compound 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine (compound 6) Dissolve in pyridine, slowly add dimethyl aluminum chloride dropwise under ice bath conditions, raise to room temperature and stir for 7 days, add 30% L-tartaric acid solution to quench the reaction, add ethyl acetate to dilute, separate the organic phase, and concentrate under reduced pressure , Compound 7 was obtained by silica gel column chromatography; wherein, the molar ratio of intermediate 5: compound 6: dimethylaluminum chloride = 1.0: 1.0~5.0: 0.1~1.0.

本发明的2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成反应路线如下:2-ethylbutyl ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine) of the present invention The synthesis reaction route of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound is as follows:

具体反应步骤如下:The specific reaction steps are as follows:

(1)在室温下,置换气体,将1,2-双(氯二甲基硅基)乙烷的四氢呋喃溶液加入到4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪(化合物2)的四氢呋喃溶液中,搅拌10min;加入二异丙胺,搅拌5min;放置-78℃低温恒温搅拌器中降温,搅拌至少20min,缓慢滴正丁基锂,搅拌30min;将2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯(化合物8)溶于四氢呋喃中,滴加到体系中,搅拌2h;加入1M柠檬酸溶液,升温至0℃,搅拌20min;分离有机相,减压浓缩得到粗产物中间体9,进一步柱层析纯化得到中间体9;其中,摩尔比1,2-双(氯二甲基硅基)乙烷:化合物2:二异丙胺:化合物8=0.5~1.5:1.0:0.5~1.5:1.0~3.0;(1) At room temperature, replace the gas and add the tetrahydrofuran solution of 1,2-bis(chlorodimethylsilyl)ethane to 4-amino-7-bromopyrrolo[2,1-F][1, 2,4] triazine (compound 2) in tetrahydrofuran solution, stir for 10 minutes; add diisopropylamine, stir for 5 minutes; place in a -78°C low temperature constant temperature stirrer to cool down, stir for at least 20 minutes, slowly drop n-butyllithium, and stir for 30 minutes ; Dissolve 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranofuranoic acid-γ-lactone (compound 8) in tetrahydrofuran, add it dropwise to the system, and stir for 2h; Add 1M citric acid solution, raise the temperature to 0°C, and stir for 20 minutes; separate the organic phase and concentrate under reduced pressure to obtain the crude product Intermediate 9, which is further purified by column chromatography to obtain Intermediate 9; where the molar ratio is 1,2-bis(chlorobis) Methylsilyl)ethane: Compound 2: Diisopropylamine: Compound 8=0.5~1.5: 1.0: 0.5~1.5: 1.0~3.0;

(2)置换气体,将中间体9溶于二氯甲烷中,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,加入三氟乙酸,搅拌10min,滴加三氟甲磺酸三甲基硅酯,搅拌30min,加入三甲基氰硅烷,搅拌2h。淬灭反应,升温至室温,分离有机相,减压浓缩,硅胶柱层析得到中间体10,其中,摩尔比中间体9:三氟乙酸:三氟甲磺酸三甲基硅酯:三甲基氰硅烷=1.0:1.0~5.0:1.0~10.0:1.0~10.0;(2) Replace the gas, dissolve intermediate 9 in methylene chloride, place it in a -78°C low temperature constant temperature stirrer to cool down, stir for at least 20 minutes, add trifluoroacetic acid, stir for 10 minutes, add trimethyl trifluoromethanesulfonate dropwise Silyl ester, stir for 30 minutes, add trimethylsilyl cyanide, and stir for 2 hours. Quench the reaction, raise the temperature to room temperature, separate the organic phase, concentrate under reduced pressure, and perform silica gel column chromatography to obtain intermediate 10, in which the molar ratio of intermediate 9: trifluoroacetic acid: trimethylsilyl trifluoromethanesulfonate: trimethyl Silane cyanide=1.0: 1.0~5.0: 1.0~10.0: 1.0~10.0;

(3)置换气体,将中间体10溶于二氯甲烷,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,滴加三氯化硼,升温至-40℃,搅拌2h,降温至-78℃,滴加干燥的甲醇;将干燥的三乙胺溶于干燥的甲醇,然后滴入反应体系中,滴入完毕,升温至室温,减压浓缩,硅胶柱层析得到中间体11,其中,摩尔比中间体10:三氯化硼=1.0:1.0~10.0;(3) Replace the gas, dissolve intermediate 10 in methylene chloride, place it in a -78°C low temperature constant temperature stirrer to cool down, stir for at least 20 minutes, add boron trichloride dropwise, raise the temperature to -40°C, stir for 2 hours, and cool to - At 78°C, dry methanol was added dropwise; dry triethylamine was dissolved in dry methanol, and then dropped into the reaction system. After the dropwise addition was completed, the temperature was raised to room temperature, concentrated under reduced pressure, and silica gel column chromatography was performed to obtain intermediate 11, in which , molar ratio of intermediate 10: boron trichloride = 1.0: 1.0~10.0;

(4)置换气体,将中间体11与光化学纯化合物2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸(化合物6)溶于吡啶中,冰浴条件下,缓慢滴加二甲基氯化铝,升至室温搅拌7d,加入30%L-酒石酸溶液淬灭反应,加入乙酸乙酯稀释,分离有机相,减压浓缩,硅胶柱层析得到化合物12;其中,摩尔比中间体11:化合物6:二甲基氯化铝=1.0:1.0~5.0:0.1~1.0。(4) Replace the gas and combine intermediate 11 with the photochemically pure compound 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine (compound 6) Dissolve in pyridine, slowly add dimethyl aluminum chloride dropwise under ice bath conditions, raise to room temperature and stir for 7 days, add 30% L-tartaric acid solution to quench the reaction, add ethyl acetate to dilute, separate the organic phase, and concentrate under reduced pressure , Compound 12 was obtained by silica gel column chromatography; wherein, the molar ratio of intermediate 11: compound 6: dimethylaluminum chloride = 1.0: 1.0~5.0: 0.1~1.0.

相对现有技术,本发明技术方案带来的有益技术效果:Compared with the existing technology, the technical solution of the present invention brings beneficial technical effects:

本发明通过化学方法成功合成了2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸和2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸两种氟代瑞德西韦药物,对核苷类药物改性及设计提供全新途径。The present invention successfully synthesizes 2-ethylbutyl ((S)-((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2 ,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine and 2 -Ethylbutyl((S)-((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl )-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine Two fluorinated remdesivir drugs, Modification and design of nucleoside drugs provide new ways.

本发明的合成方法路线短,步骤操作简单,收率相对较高(每一步反应收率均达到55以上),有利于实现扩大生产。The synthesis method of the present invention has a short route, simple steps and relatively high yield (the reaction yield of each step reaches more than 55%), which is beneficial to expanding production.

附图说明Description of the drawings

图1为2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的1H NMR(400MHz,methanol-d4,25℃)。Figure 1 shows 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine 1 H NMR of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound (400MHz ,methanol-d 4 ,25℃).

图2为2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的19F NMR(376MHz,methanol-d4,25℃)。Figure 2 shows 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine) 19 F NMR of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound (376MHz ,methanol-d 4 ,25℃).

图3为2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的19F NMR(376MHz,methanol-d4,25℃)。Figure 3 shows 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine) 19 F NMR of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound (376MHz ,methanol-d 4 ,25℃).

图4为2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的31P NMR(162MHz,methanol-d4,25℃)。Figure 4 is 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine 31 P NMR of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound (162MHz ,methanol-d 4 ,25℃).

图5为2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的31P NMR(162MHz,methanol-d4,25℃)。Figure 5 is 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine 31 P NMR of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound (162MHz ,methanol-d 4 ,25℃).

图6为2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的13C NMR(100MHz,methanol-d4,25℃)。Figure 6 is 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazine 13 C NMR of -7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound (100MHz ,methanol-d 4 ,25℃).

具体实施方式Detailed ways

以下具体实施例旨在进一步说明本发明内容,而不是限制权利要求的保护范围。The following specific examples are intended to further illustrate the present invention, but are not intended to limit the scope of the claims.

以下实施例中涉及的化学试剂如果没有特殊说明,均为常规的市售分析纯试剂。Unless otherwise specified, the chemical reagents involved in the following examples are all conventional commercially available analytically pure reagents.

实施例1Example 1

(1)中间体3的合成(1) Synthesis of intermediate 3

将4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪(化合物2)(321mg,1.515mmol)称于干燥的50mL圆底烧瓶,置换气体三次,加入四氢呋喃(25.8mL),室温下搅拌5min;称1,2-双(氯二甲基硅基)乙烷(358.7mg,1.667mmol)于干燥的5mL圆底烧瓶,加入干燥的四氢呋喃(1.6mL)使之溶解并加入到反应体系中,室温下搅拌10min,加入二异丙胺(234μL,1.667mmol),室温下搅拌5min,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,缓慢滴正丁基锂(1.6M in n-hexane,4.07mL,6.515mmol),搅拌30min;将2-脱氧-2-氟-3,5-二-O-苄基-D-核糖酸-γ-内酯(化合物1)(1.0g,3.029mmol)称于干燥的5mL圆底烧瓶,加入四氢呋喃(1.6mL)溶解,滴加到体系中,搅拌2h,TLC监控反应。Weigh 4-amino-7-bromopyrrolo[2,1-F][1,2,4]triazine (compound 2) (321 mg, 1.515 mmol) into a dry 50 mL round-bottomed flask, replace the gas three times, and add Tetrahydrofuran (25.8 mL), stir at room temperature for 5 min; weigh 1,2-bis(chlorodimethylsilyl)ethane (358.7 mg, 1.667 mmol) into a dry 5 mL round-bottomed flask, and add dry tetrahydrofuran (1.6 mL) Dissolve it and add it to the reaction system, stir at room temperature for 10 minutes, add diisopropylamine (234 μL, 1.667 mmol), stir at room temperature for 5 minutes, place it in a -78°C low-temperature stirrer to cool down, stir for at least 20 minutes, and slowly drip n-butylamine Lithium (1.6M in n-hexane, 4.07mL, 6.515mmol), stir for 30min; 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-ribo-γ-lactone ( Compound 1) (1.0g, 3.029mmol) was weighed into a dry 5mL round-bottomed flask, added tetrahydrofuran (1.6mL) to dissolve, added dropwise to the system, stirred for 2h, and monitored the reaction with TLC.

监控反应完成,加入1M柠檬酸溶液(16mL)淬灭反应,升温至0℃,分离有机相,减压浓缩得到粗产物,溶解,加入硅胶拌样,硅胶柱层析得到中间体3(421mg,60%,石油醚:乙酸乙酯=1:2,Rf=0.25)。Monitor the completion of the reaction, add 1M citric acid solution (16 mL) to quench the reaction, raise the temperature to 0°C, separate the organic phase, concentrate under reduced pressure to obtain the crude product, dissolve it, add silica gel to mix the sample, and perform silica gel column chromatography to obtain intermediate 3 (421 mg, 60%, petroleum ether: ethyl acetate = 1:2, R f = 0.25).

(2)中间体4的合成(2) Synthesis of intermediate 4

将中间体3(421mg,0.907mmol)称于25mL反应瓶,置换气体三次,加入二氯甲烷(12mL),搅拌溶解,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,加入三氟乙酸(208μL,2.721mmol),搅拌10min,滴加三氟甲磺酸三甲基硅酯(0.98mL,5.442mmol),搅拌30min,加入三甲基氰硅烷(0.68mL,5.442mmol),搅拌2h,TLC监控反应。Weigh intermediate 3 (421 mg, 0.907 mmol) into a 25 mL reaction flask, replace the gas three times, add methylene chloride (12 mL), stir to dissolve, place in a -78°C low-temperature stirrer to cool down, stir for at least 20 min, and add trifluoroacetic acid (208μL, 2.721mmol), stir for 10min, add trimethylsilyl trifluoromethanesulfonate (0.98mL, 5.442mmol) dropwise, stir for 30min, add trimethylsilyl cyanide (0.68mL, 5.442mmol), stir for 2h. Reactions were monitored by TLC.

监控反应完成,淬灭反应,升温至室温,分离有机相,减压浓缩,拌样,硅胶柱层析得到中间体4(259mg,60%,石油醚:乙酸乙酯=1:2,Rf=0.7)。Monitor the completion of the reaction, quench the reaction, warm to room temperature, separate the organic phase, concentrate under reduced pressure, mix the sample, and obtain intermediate 4 (259 mg, 60%, petroleum ether: ethyl acetate = 1:2, R f =0.7).

(3)中间体5的合成(3) Synthesis of intermediate 5

将中间体4(231mg,0.488mmol)称于25mL瓶,置换气体三次,加入二氯甲烷(2.7mL),搅拌溶解,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,滴加三氯化硼(1Min methylene chloride,3.71mL,3.71mmol),升温至-40℃,搅拌2h,TLC监控反应。Weigh Intermediate 4 (231 mg, 0.488 mmol) into a 25 mL bottle, replace the gas three times, add methylene chloride (2.7 mL), stir to dissolve, place in a -78°C low-temperature stirrer to cool down, stir for at least 20 min, add trichloride dropwise Boron (1Min methylene chloride, 3.71mL, 3.71mmol) was heated to -40°C, stirred for 2 hours, and the reaction was monitored by TLC.

监控反应完成,降温至-78℃,滴加干燥的甲醇(1.08mL);将干燥的三乙胺(1.4mL)溶于干燥的甲醇(2.2mL),然后滴入反应体系中,滴入完毕,升温至室温,减压浓缩,用甲醇溶解,加入硅胶拌样,用乙酸乙酯硅胶柱层析,得到产物1-氰基-1-C-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-2-脱氧-2-氟-D-核糖中间体5(137mg,96%,石油醚:乙酸乙酯=1:4,Rf=0.2)。Monitor the completion of the reaction, cool down to -78°C, and add dry methanol (1.08 mL) dropwise; dissolve dry triethylamine (1.4 mL) in dry methanol (2.2 mL), and then drop it into the reaction system until the addition is completed. , warmed to room temperature, concentrated under reduced pressure, dissolved in methanol, added silica gel to mix the sample, and used ethyl acetate silica gel column chromatography to obtain the product 1-cyano-1-C-(4-aminopyrrolo[2,1-f ][1,2,4]triazin-7-yl)-2-deoxy-2-fluoro-D-ribose intermediate 5 (137 mg, 96%, petroleum ether: ethyl acetate = 1: 4, R f = 0.2).

[α]D 25=-51.1(c 1.0,C2H5OH);m.p.:166-169℃;[α] D 25 =-51.1 (c 1.0, C 2 H 5 OH); mp: 166-169°C;

1H-NMR(400MHz,methanol-d4):δ7.89(s,1H),7.00(d,J=4.8Hz,1H),6.90(d,J=4.8Hz,1H),5.47(dd,J=53.8,4.0Hz,1H),4.68(s,2H),4.30-4.21(m,2H),3.95(dd,J=12.6,2.0Hz,1H),3.75(dd,J=12.6,4.0Hz,1H); 1 H-NMR (400MHz, methanol-d 4 ): δ7.89 (s, 1H), 7.00 (d, J = 4.8Hz, 1H), 6.90 (d, J = 4.8Hz, 1H), 5.47 (dd, J=53.8,4.0Hz,1H),4.68(s,2H),4.30-4.21(m,2H),3.95(dd,J=12.6,2.0Hz,1H),3.75(dd,J=12.6,4.0Hz ,1H);

13C-NMR(100MHz,methanol-d4):δ157.20,148.53,123.67(d,J=5.0Hz,1C),118.15,116.18(d,J=7.2Hz,1C),112.47,102.75,93.69(d,J=200.4Hz,1C),85.06,79.09(d,J=20.5Hz,1C),70.52(d,J=16.7Hz,1C),61.76; 13 C-NMR (100MHz, methanol-d 4 ): δ157.20, 148.53, 123.67 (d, J = 5.0Hz, 1C), 118.15, 116.18 (d, J = 7.2Hz, 1C), 112.47, 102.75, 93.69 (d ,J=200.4Hz,1C),85.06,79.09(d,J=20.5Hz,1C),70.52(d,J=16.7Hz,1C),61.76;

19F NMR(376MHz,methanol-d4):δ-197.79--197.98(m,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-197.79--197.98 (m, 1F);

19F NMR(376MHz,methanol-d4):δ-197.88(s,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-197.88 (s, 1F);

HRMS(ESI)m/z calcd for C12H12FN5O3Na+(M+Na)+316.0816,found 316.0816.HRMS(ESI)m/z calcd for C 12 H 12 FN 5 O 3 Na + (M+Na) + 316.0816,found 316.0816.

(4)化合物7的合成(4) Synthesis of compound 7

将中间体5(50mg,0.171mmol)和光化学纯化合物2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸(化合物6)(169mg,0.341mmol)加入到10mL的圆底烧瓶中,置换气体三次,加入干燥的吡啶(1.7mL),冰浴条件下降温搅拌10min,缓慢滴加二甲基氯化铝(1M in heptane,86μL,0.086mmol),升至室温搅拌7d,TLC监控反应。Intermediate 5 (50 mg, 0.171 mmol) and the photochemically pure compound 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine (compound 6) (169 mg, 0.341 mmol) was added to a 10 mL round-bottomed flask, replaced the gas three times, added dry pyridine (1.7 mL), cooled and stirred for 10 min in an ice bath, and slowly added dimethylaluminum chloride (1 M in heptane, 86 μL, 0.086 mmol), raised to room temperature and stirred for 7 days, and TLC monitored the reaction.

监控反应完成,加入30%L-酒石酸溶液(1mL)淬灭反应,加入乙酸乙酯稀释,分离有机相,减压浓缩拌样,硅胶柱层析得到化合物7(66mg,64%,石油醚:乙酸乙酯=1:4,Rf=0.4)。Monitor the completion of the reaction, add 30% L-tartaric acid solution (1mL) to quench the reaction, add ethyl acetate to dilute, separate the organic phase, concentrate under reduced pressure and mix the sample, silica gel column chromatography to obtain compound 7 (66mg, 64%, petroleum ether: Ethyl acetate=1:4, R f =0.4).

1H NMR(400MHz,methanol-d4):δ7.89(s,1H),7.35-7.30(m,2H),7.24-7.16(m,3H),5.48(dd,J=53.4,4.1Hz,1H),4.51-4.46(m,1H),4.39-4.23(m,3H),4.04-4.00(m,1H),3.95-3.91(m,2H),1.48-1.42(m,1H),1.34-1.27(m,8H),0.87-0.83(m,6H); 1 H NMR (400MHz, methanol-d 4 ): δ7.89 (s, 1H), 7.35-7.30 (m, 2H), 7.24-7.16 (m, 3H), 5.48 (dd, J = 53.4, 4.1Hz, 1H),4.51-4.46(m,1H),4.39-4.23(m,3H),4.04-4.00(m,1H),3.95-3.91(m,2H),1.48-1.42(m,1H),1.34- 1.27(m,8H),0.87-0.83(m,6H);

19F NMR(376MHz,methanol-d4):δ-196.98--197.18(m,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-196.98--197.18 (m, 1F);

19F NMR(376MHz,methanol-d4):δ-197.08(s,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-197.08 (s, 1F);

31PNMR(162MHz,methanol-d4):δ3.68-3.54(m,1P); 31 PNMR (162MHz, methanol-d 4 ): δ3.68-3.54 (m, 1P);

31PNMR(162MHz,methanol-d4):δ3.61(s,1P); 31 PNMR (162MHz, methanol-d 4 ): δ3.61 (s, 1P);

13C NMR(100MHz,methanol-d4):δ174.99,174.94,157.17,152.16,125.10,148.59,130.76,126.13,123.31,123.26,121.35,121.31,118.21,115.78,115.70,112.33,102.77,94.62,92.63,82.39,82.31,79.41,79.20,70.57,70.40,68.09,66.27,66.22,51.50,41.67,24.19,20.61,20.54,11.33,11.28; 13 C NMR (100MHz, methanol-d 4 ): δ174.99,174.94,157.17,152.16,125.10,148.59,130.76,126.13,123.31,123.26,121.35,121.31,118.21,115.78,11 5.70,112.33,102.77,94.62,92.63, 82.39,82.31,79.41,79.20,70.57,70.40,68.09,66.27,66.22,51.50,41.67,24.19,20.61,20.54,11.33,11.28;

HRMS(ESI)m/z calcd for C27H34FN6O7PNa+(M+Na)+627.2103,found 627.2107.HRMS(ESI)m/z calcd for C 27 H 34 FN 6 O 7 PNa + (M+Na) + 627.2103, found 627.2107.

实施例2Example 2

(1)中间体9的合成(1) Synthesis of Intermediate 9

参考A.U,Patent 2015238851A1使用反应条件4,虽然产率低,只有20%,但拿到了目标产物,为后面反应条件的筛选点板有了对照点。反应条件5中添加NaH,产率提高到41%,放大10倍投料,产率降低至34%。反应条件7,刚开始尝试,产率只有42%。后面把反应溶剂增加,反应体系浓度降低,使用反应条件8,产率达到68%。此条件放大10倍投料,产率没有明显变化。因此非天然碱基与核糖中心连接的最佳反应条件是条件8。如下表所示:Referring to A.U. Patent 2015238851A1, reaction condition 4 was used. Although the yield was low, only 20%, the target product was obtained, which provided a control point for the subsequent screening of reaction conditions. When NaH was added in reaction condition 5, the yield increased to 41%. When the feed was amplified 10 times, the yield decreased to 34%. Reaction condition 7, when I first tried it, the yield was only 42%. Later, the reaction solvent was increased and the concentration of the reaction system was reduced. Using reaction conditions 8, the yield reached 68%. Under this condition, the feed was amplified 10 times, and the yield did not change significantly. Therefore, the optimal reaction condition for connecting unnatural bases to the ribose center is condition 8. As shown in the following table:

以下为具体实施方案:将4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪(化合物2)(433.4mg,2.0446mmol)称于干燥的50mL圆底烧瓶,置换气体三次,在氮气保护下加入干燥的四氢呋喃(20mL),室温下搅拌5min;称1,2-双(氯二甲基硅基)乙烷(484.2mg,2.249mmol)于干燥的5mL圆底烧瓶,加入干燥的四氢呋喃(3mL)使之溶解并加入到反应体系中,室温下搅拌10min,加入二异丙胺(0.32mL,2.249mmol),室温下搅拌5min,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,缓慢滴加正丁基锂(1.6M in n-hexane,5.5mL,8.792mmol),滴加完毕后,在-78℃下搅拌30min;将2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯(化合物8)(1.35g,4.0893mmol)称于干燥的5mL圆底烧瓶,加入干燥的四氢呋喃(3mL)使之溶解并缓慢滴加到反应体系中,滴加完毕后,在-78℃下搅拌2h,TLC监控反应,用石油醚:乙酸乙酯=1:2爬板。The following is a specific embodiment: 4-amino-7-bromopyrrolo[2,1-F][1,2,4]triazine (compound 2) (433.4mg, 2.0446mmol) was weighed into a dry 50mL round bottom Flask, replace the gas three times, add dry tetrahydrofuran (20mL) under nitrogen protection, stir at room temperature for 5 minutes; weigh 1,2-bis(chlorodimethylsilyl)ethane (484.2mg, 2.249mmol) into dry 5mL In a round-bottomed flask, add dry tetrahydrofuran (3 mL) to dissolve it and add it to the reaction system. Stir at room temperature for 10 min. Add diisopropylamine (0.32 mL, 2.249 mmol). Stir at room temperature for 5 min. Place at -78°C and stir at low temperature. Cool down the temperature in the device, stir for at least 20 minutes, slowly add n-butyllithium (1.6M in n-hexane, 5.5mL, 8.792mmol) dropwise. After the dropwise addition is completed, stir at -78°C for 30min; 2-deoxy-2- Fluoro-3,5-di-O-benzyl-D-arabinofuranosyl-γ-lactone (compound 8) (1.35g, 4.0893mmol) was weighed into a dry 5mL round-bottom flask, and dry tetrahydrofuran (3mL ) to dissolve and slowly drop it into the reaction system. After the dropwise addition is completed, stir at -78°C for 2 hours. Monitor the reaction with TLC and use petroleum ether: ethyl acetate = 1:2 to climb the plate.

监控反应完成,加入1M柠檬酸溶液(16mL)淬灭反应,升温至0℃,分离有机相,减压浓缩得到粗产物,溶解,加入硅胶拌样,硅胶柱层析得到中间体9(542mg,68%,石油醚:乙酸乙酯=1:2,Rf=0.25)。Monitor the completion of the reaction, add 1M citric acid solution (16 mL) to quench the reaction, raise the temperature to 0°C, separate the organic phase, concentrate under reduced pressure to obtain the crude product, dissolve it, add silica gel to mix the sample, and perform silica gel column chromatography to obtain intermediate 9 (542 mg, 68%, petroleum ether: ethyl acetate = 1:2, R f = 0.25).

(2)中间体10的合成(2) Synthesis of intermediate 10

对1-C-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-2-脱氧-2-氟-3,5-二-O-苄基-D-核糖(中间体4)进行氰基化反应,刚开始控制反应温度为-78℃时,反应过程中,会有固体析出,按照反应操作进行反应,点板发现有原料未反应完,产率为60%(反应条件1)。用1-C-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖(中间体9),再一次试反应,实验现象一样,产率为65%(反应条件2上半)。分析原料未反应完的原因,因为瑞德西韦合成中氰基化反应投料当量比是可以把原料反应完的,结合反应过程中出现固体,意识到在-78℃下原料不能很好的溶解到溶剂中,因此采取升温措施。以1-C-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖(中间体9)为反应底物,使反应温度从-78℃缓慢升温,观察固体溶解情况,直到-40℃,溶液澄清,加入三氟乙酸搅拌一会后加入三氟甲磺酸三甲基硅酯和三甲基氰硅烷,搅拌2h点板,发现原料反应完全,产率为83%(反应条件2下半)。接下来,氰基化反应的温度控制在了-40℃,具体内容如下表所示:p-1-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-deoxy-2-fluoro-3,5-di-O-benzyl D-ribose (intermediate 4) was subjected to a cyanolation reaction. When the reaction temperature was initially controlled to -78°C, solids would precipitate during the reaction. The reaction was carried out according to the reaction operation. It was found on the spot board that some raw materials had not been completely reacted. , the yield is 60% (reaction condition 1). 1-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-deoxy-2-fluoro-3,5-di-O-benzyl -D-arabinofuranose (intermediate 9), try the reaction again, the experimental phenomenon is the same, the yield is 65% (upper half of reaction condition 2). Analyze the reason why the raw materials have not been completely reacted, because the equivalent ratio of the cyanation reaction in the synthesis of remdesivir can complete the reaction of the raw materials. During the combined reaction, solids appear, and we realize that the raw materials cannot dissolve well at -78°C. into the solvent, so heating measures are taken. 1-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2-deoxy-2-fluoro-3,5-di-O-benzyl Use methyl-D-arabinofuranose (intermediate 9) as the reaction substrate, slowly raise the reaction temperature from -78°C, and observe the dissolution of the solid until -40°C. When the solution is clear, add trifluoroacetic acid and stir for a while, then add trifluoroacetic acid. Trimethylsilyl fluomethanesulfonate and trimethylsilyl cyanide were stirred for 2 hours and found to be completely reacted with a yield of 83% (lower half of reaction conditions 2). Next, the temperature of the cyanation reaction was controlled at -40°C. The specific contents are as shown in the table below:

以下为具体实施方案:将中间体9(50mg,0.108mmol)称于干燥的10mL圆底烧瓶,置换气体三次,在氮气保护下加入干燥的二氯甲烷(1.4mL),搅拌溶解,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,加入三氟乙酸(24μL,0.323mmol),搅拌10min,滴加三氟甲磺酸三甲基硅酯(117μL,0.648mmol),搅拌30min,加入三甲基氰硅烷(81μL,0.648mmol),搅拌2h,TLC监控反应,用石油醚:乙酸乙酯=1:2爬板。The following is a specific implementation: Weigh Intermediate 9 (50 mg, 0.108 mmol) into a dry 10 mL round-bottomed flask, replace the gas three times, add dry dichloromethane (1.4 mL) under nitrogen protection, stir to dissolve, and place at -78 Cool the temperature in a low temperature constant temperature stirrer at ℃, stir for at least 20 minutes, add trifluoroacetic acid (24 μL, 0.323 mmol), stir for 10 minutes, add trimethylsilyl trifluoromethanesulfonate (117 μL, 0.648 mmol) dropwise, stir for 30 minutes, add trifluoromethanesulfonate Methyl cyanide silane (81 μL, 0.648 mmol), stir for 2 hours, monitor the reaction with TLC, and use petroleum ether: ethyl acetate = 1:2 to climb the plate.

监控反应完成,淬灭反应,升温至室温,分离有机相,减压浓缩,拌样,硅胶柱层析得到中间体10(33mg,65%,石油醚:乙酸乙酯=1:2,Rf=0.7)。Monitor the reaction to complete, quench the reaction, warm to room temperature, separate the organic phase, concentrate under reduced pressure, mix the sample, and obtain intermediate 10 (33 mg, 65%, petroleum ether: ethyl acetate = 1:2, R f =0.7).

(3)中间体11的合成(3) Synthesis of intermediate 11

将中间体10(189mg,0.399mmol)称于干燥的25mL圆底烧瓶,置换气体三次,在氮气保护下,加入干燥的二氯甲烷(2.2mL),搅拌溶解,放置-78℃低温恒温搅拌器中降温,搅拌至少20min,滴加三氯化硼(1M in methylene chloride,3.04mL,3.04mmol),滴加完毕,升温至-40℃,搅拌2h,TLC监控反应,用石油醚:乙酸乙酯=1:1爬板。Weigh Intermediate 10 (189 mg, 0.399 mmol) into a dry 25 mL round-bottomed flask, replace the gas three times, add dry methylene chloride (2.2 mL) under nitrogen protection, stir to dissolve, and place in a -78°C low temperature constant temperature stirrer. Lower the temperature in medium, stir for at least 20 minutes, add boron trichloride (1M in methylene chloride, 3.04mL, 3.04mmol) dropwise. After the dropwise addition is completed, raise the temperature to -40°C, stir for 2h, monitor the reaction with TLC, use petroleum ether: ethyl acetate =1:1 climbing board.

监控反应完成,降温至-78℃,滴加干燥的甲醇(0.88mL);将干燥的三乙胺(1.44mL)溶于干燥的甲醇(1.76mL),然后滴入反应体系中,滴入完毕,升温至室温,减压浓缩,用甲醇溶解,加入硅胶拌样,用乙酸乙酯硅胶柱层析,得到中间体11(105mg,90%,石油醚:乙酸乙酯=1:4,Rf=0.2)。Monitor the completion of the reaction, cool down to -78°C, and add dry methanol (0.88mL) dropwise; dissolve dry triethylamine (1.44mL) in dry methanol (1.76mL), then drop it into the reaction system, and the dropwise addition is complete , warmed to room temperature, concentrated under reduced pressure, dissolved in methanol, added silica gel to mix the sample, and used ethyl acetate silica gel column chromatography to obtain intermediate 11 (105 mg, 90%, petroleum ether: ethyl acetate = 1: 4, R f =0.2).

1HNMR(400MHz,methanol-d4):δ7.88(s,1H),6.91-6.88(m,2H),5.67(d,J=49.6,Hz,1H),4.42-4.31(m,2H),3.83-3.75(m,2H); 1 HNMR (400MHz, methanol-d 4 ): δ7.88 (s, 1H), 6.91-6.88 (m, 2H), 5.67 (d, J = 49.6, Hz, 1H), 4.42-4.31 (m, 2H) ,3.83-3.75(m,2H);

13C-NMR(100MHz,methanol-d4):δ157.03,148.27,122.99,116.98,116.88,116.79,111.64,102.73,100.57(d,J=198.8Hz,1C),,88.61,79.47(d,J=31.3Hz,1C),77.07(d,J=26.82Hz,1C),62.44; 13 C-NMR (100MHz, methanol-d 4 ): δ157.03,148.27,122.99,116.98,116.88,116.79,111.64,102.73,100.57(d,J=198.8Hz,1C),,88.61,79.47(d,J= 31.3Hz, 1C), 77.07 (d, J = 26.82Hz, 1C), 62.44;

19F NMR(376MHz,methanol-d4):δ-186.37--186.55(m,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-186.37--186.55 (m, 1F);

19F NMR(376MHz,methanol-d4):δ-186.46(s,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-186.46 (s, 1F);

HRMS(ESI)m/z calcd for C12H12FN5O3Na+(M+Na)+316.0816,found 316.0818.HRMS(ESI)m/z calcd for C 12 H 12 FN 5 O 3 Na + (M+Na) + 316.0816, found 316.0818.

(4)化合物12的合成(4) Synthesis of compound 12

将中间体11(50mg,0.171mmol)和光化学纯化合物2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸(化合物6)(169mg,0.341mmol)加入到10mL的圆底烧瓶中,置换气体三次,加入干燥的吡啶(1.7mL),冰浴条件下降温搅拌10min,缓慢滴加二甲基氯化铝(1M in heptane,86μL,0.086mmol),升至室温搅拌7d,TLC监控反应。Intermediate 11 (50 mg, 0.171 mmol) and photochemically pure compound 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine (compound 6) (169 mg, 0.341 mmol) was added to a 10 mL round-bottomed flask, replaced the gas three times, added dry pyridine (1.7 mL), cooled and stirred for 10 min in an ice bath, and slowly added dimethylaluminum chloride (1 M in heptane, 86 μL, 0.086 mmol), raised to room temperature and stirred for 7 days, and TLC monitored the reaction.

监控反应完成,加入30%L-酒石酸溶液(1mL)淬灭反应,加入乙酸乙酯稀释,分离有机相,减压浓缩拌样,硅胶柱层析得到化合物12(58.8mg,57%,石油醚:乙酸乙酯=1:4,Rf=0.4)Monitor the completion of the reaction, add 30% L-tartaric acid solution (1mL) to quench the reaction, add ethyl acetate to dilute, separate the organic phase, concentrate under reduced pressure and mix the sample, silica gel column chromatography to obtain compound 12 (58.8 mg, 57%, petroleum ether) : Ethyl acetate = 1: 4, R f = 0.4)

1H NMR(400MHz,methanol-d4):δ7.89(s,1H),7.36-7.16(m,5H),6.90(d,J=4.6Hz,1H),6.82(d,J=4.6Hz,1H),5.69(d,J=49.14Hz,1H),4.50-4.27(m,4H),4.05-3.94(m,3H),1.50-1.42(m,1H),1.36-1.29(m,8H),0.88-0.84(m,6H); 1 H NMR (400MHz, methanol-d 4 ): δ7.89 (s, 1H), 7.36-7.16 (m, 5H), 6.90 (d, J = 4.6Hz, 1H), 6.82 (d, J = 4.6Hz ,1H),5.69(d,J=49.14Hz,1H),4.50-4.27(m,4H),4.05-3.94(m,3H),1.50-1.42(m,1H),1.36-1.29(m,8H ),0.88-0.84(m,6H);

19F NMR(376MHz,methanol-d4):δ-186.37--186.55(m,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-186.37--186.55 (m, 1F);

19F NMR(376MHz,methanol-d4):δ-186.46(s,1F); 19 F NMR (376MHz, methanol-d 4 ): δ-186.46 (s, 1F);

31PNMR(162MHz,methanol-d4):δ3.50-3.35(m,1P); 31 PNMR (162MHz, methanol-d 4 ): δ3.50-3.35 (m, 1P);

31PNMR(162MHz,methanol-d4):δ3.43(s,1P); 31 PNMR (162MHz, methanol-d 4 ): δ3.43 (s, 1P);

13C NMR(100MHz,methanol-d4):δ174.96,174.92,158.85,157.03,152.21,152.14,148.40,130.79,126.13,121.42,124.37,116.58,116.50,111.67,102.76,101.14,99.18,86.47,79.51,76.79,68.11,66.46,51.54,41.66,24.21,20.61,20.54,11.34,11.29; 13 C NMR (100MHz, methanol-d 4 ): δ174.96,174.92,158.85,157.03,152.21,152.14,148.40,130.79,126.13,121.42,124.37,116.58,116.50,111.67,10 2.76,101.14,99.18,86.47,79.51, 76.79,68.11,66.46,51.54,41.66,24.21,20.61,20.54,11.34,11.29;

HRMS(ESI)m/z calcd for C27H34FN6O7PNa+(M+Na)+627.2103,found 627.2107.HRMS(ESI)m/z calcd for C 27 H 34 FN 6 O 7 PNa + (M+Na) + 627.2103, found 627.2107.

以上所述,只是本发明的较佳实施例而已,本发明并不局限于上述实施方式,只要其以相同的手段达到本发明的技术效果,都应属于本发明的保护范围。在本发明的保护范围内其技术方案和/或实施方式可以有各种不同的修改和变化。The above are only preferred embodiments of the present invention. The present invention is not limited to the above-mentioned embodiments. As long as the technical effects of the present invention are achieved by the same means, they shall fall within the protection scope of the present invention. Various modifications and changes may be made to the technical solutions and/or implementations within the scope of the present invention.

Claims (10)

1.一种2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:包括以下步骤:1. A 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]tri Synthetic method of azine-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound, It is characterized by: including the following steps: 1)将2-脱氧-2-氟-3,5-二-O-苄基-D-核糖酸-γ-内酯与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪通过糖碳苷化反应,得到中间体3;1) Combine 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-ribono-γ-lactone and 4-amino-7-bromopyrrolo[2,1-F][1 ,2,4]Triazine obtains intermediate 3 through sugar carbonation reaction; 2)将中间体3与三氟乙酸、三氟甲磺酸三甲基硅酯和三甲基氰硅烷通过氰基化反应,得到中间体4;2) React intermediate 3 with trifluoroacetic acid, trimethylsilyl trifluoromethanesulfonate and trimethylsilyl cyanide through cyanation to obtain intermediate 4; 3)将中间体4通过脱苄基保护基反应,得到中间体5;3) React intermediate 4 through debenzylation protecting group to obtain intermediate 5; 4)将中间体5与2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸通过磷酸化反应,得到2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物;4) Phosphate the intermediate 5 with 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine to obtain 2-ethylbutyl Base ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5- Cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound; 其中,所述2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的结构式如下:Wherein, the 2-ethylbutyl ((S)-(((2R,3R,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]tri The structural formula of the azine-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound is as follows: 中间体3、4、5结构依次如下:The structures of intermediates 3, 4, and 5 are as follows: 2.根据权利要求1所述的一种2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述糖碳苷化反应的过程为:将1,2-双(氯二甲基硅基)乙烷溶液与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪溶液混合,搅拌5~20min,再加入二异丙胺,搅拌3~10min,再放置在-50℃以下低温环境中,搅拌至少20min,再缓慢滴加正丁基锂,搅拌15~60min,再滴加2-脱氧-2-氟-3,5-二-O-苄基-D-核糖酸-γ-内酯溶液,搅拌1~5小时,再加入柠檬酸溶液,升温至0~5℃,搅拌10~30min。2. A kind of 2-ethylbutyl ((S)-(((2R,3R,4R,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 1 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine A method for synthesizing acid compounds, characterized in that: the process of the sugar carbonation reaction is: mixing 1,2-bis(chlorodimethylsilyl)ethane solution with 4-amino-7-bromopyrrolo[2 ,1-F][1,2,4]Triazine solution is mixed, stir for 5 to 20 minutes, then add diisopropylamine, stir for 3 to 10 minutes, then place in a low temperature environment below -50°C, stir for at least 20 minutes, and then slowly Add n-butyllithium dropwise, stir for 15 to 60 minutes, then add 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-ribono-γ-lactone solution dropwise, and stir for 1 to 5 hours. , then add citric acid solution, raise the temperature to 0~5°C, and stir for 10~30 minutes. 3.根据权利要求1所述的一种2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述氰基化反应的过程为:将中间体3溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再加入三氟乙酸,搅拌5~30min,再滴加三氟甲磺酸三甲基硅酯,搅拌10~60min,再加入三甲基氰硅烷,搅拌1~5h。3. a kind of 2-ethylbutyl ((S)-(((2R,3R,4R,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 1 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine The synthesis method of acid compounds is characterized in that: the cyanation reaction process is: dissolve intermediate 3 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, then add trifluoroacetic acid, and stir 5 to 30 minutes, then add trimethylsilyl trifluoromethanesulfonate dropwise, stir for 10 to 60 minutes, then add trimethylsilyl cyanide, and stir for 1 to 5 hours. 4.根据权利要求1所述的一种2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述脱苄基保护基反应的过程为:将中间体4溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再滴加三氯化硼,并升温至-40~-30℃,搅拌1~5h。4. a kind of 2-ethylbutyl ((S)-(((2R,3R,4R,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 1 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine The synthesis method of acid compounds is characterized in that: the process of the debenzyl protecting group reaction is: dissolve intermediate 4 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, and then add trichloride dropwise Boronize, raise the temperature to -40~-30°C, and stir for 1~5 hours. 5.根据权利要求1所述的一种2-乙基丁基((S)-(((2R,3R,4R,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述磷酸化反应的过程为:将中间体5溶于溶剂及2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸溶于溶剂,并放置在冰浴环境中,缓慢滴加二甲基氯化铝,升至室温搅拌5~10d。5. a kind of 2-ethylbutyl ((S)-(((2R,3R,4R,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 1 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine A method for synthesizing acid compounds, characterized in that: the process of the phosphorylation reaction is: dissolving intermediate 5 in a solvent and 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy) Phosphoryl)-L-alanine is dissolved in the solvent and placed in an ice bath environment. Dimethylaluminum chloride is slowly added dropwise, and the mixture is raised to room temperature and stirred for 5 to 10 days. 6.一种2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:包括以下步骤:6. A 2-ethylbutyl ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]tri Synthetic method of azine-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound, It is characterized by: including the following steps: 1)将2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪通过糖碳苷化反应,得到中间体9;1) Combine 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranosyl-γ-lactone and 4-amino-7-bromopyrrolo[2,1-F] [1,2,4] Triazine obtains intermediate 9 through sugar carbonation reaction; 2)将中间体9与三氟乙酸、三氟甲磺酸三甲基硅酯和三甲基氰硅烷通过氰基化反应,得到中间体4或中间体10;2) React intermediate 9 with trifluoroacetic acid, trimethylsilyl trifluoromethanesulfonate and trimethylsilyl cyanide through cyanation to obtain intermediate 4 or intermediate 10; 3)将中间体10通过脱苄基保护基反应,得到中间体5或中间体11;3) React intermediate 10 through debenzylation protecting group to obtain intermediate 5 or intermediate 11; 4)将中间体11与2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸通过磷酸化反应,得到2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物;4) Phosphate the intermediate 11 with 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy)phosphoryl)-L-alanine to obtain 2-ethylbutyl Base ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5- Cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound; 其中,所述2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的结构式如下:Wherein, the 2-ethylbutyl ((S)-(((2R,3R,4S,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]tri The structural formula of the azine-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine compound is as follows: 中间体9、10、11结构依次如下:The structures of intermediates 9, 10, and 11 are as follows: 7.根据权利要求6所述的一种2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述糖碳苷化反应的过程为:将1,2-双(氯二甲基硅基)乙烷溶液与4-氨基-7-溴吡咯并[2,1-F][1,2,4]三嗪溶液混合,搅拌5~20min,再加入二异丙胺,搅拌3~10min,再放置在-50℃以下低温环境中,搅拌至少20min,再缓慢滴加正丁基锂,搅拌15~60min,再滴加2-脱氧-2-氟-3,5-二-O-苄基-D-阿拉伯呋喃糖酸-γ-内酯溶液,搅拌1~5小时,再加入柠檬酸溶液,升温至0~5℃,搅拌10~30min。7. A kind of 2-ethylbutyl ((S)-(((2R,3R,4S,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 6 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine A method for synthesizing acid compounds, characterized in that: the process of the sugar carbonation reaction is: mixing 1,2-bis(chlorodimethylsilyl)ethane solution with 4-amino-7-bromopyrrolo[2 ,1-F][1,2,4]Triazine solution is mixed, stir for 5 to 20 minutes, then add diisopropylamine, stir for 3 to 10 minutes, then place in a low temperature environment below -50°C, stir for at least 20 minutes, and then slowly Add n-butyllithium dropwise and stir for 15 to 60 minutes, then add 2-deoxy-2-fluoro-3,5-di-O-benzyl-D-arabinofuranonoic acid-γ-lactone solution dropwise, and stir for 1 to 60 minutes. 5 hours, then add citric acid solution, raise the temperature to 0~5℃, and stir for 10~30min. 8.根据权利要求6所述的一种2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述氰基化反应的过程为:将中间体9溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再加入三氟乙酸,搅拌5~30min,再滴加三氟甲磺酸三甲基硅酯,搅拌10~60min,再加入三甲基氰硅烷,搅拌1~5h。8. A kind of 2-ethylbutyl ((S)-(((2R,3R,4S,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 6 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine The synthesis method of acid compounds is characterized in that: the cyanation reaction process is: dissolve intermediate 9 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, then add trifluoroacetic acid, and stir 5 to 30 minutes, then add trimethylsilyl trifluoromethanesulfonate dropwise, stir for 10 to 60 minutes, then add trimethylsilyl cyanide, and stir for 1 to 5 hours. 9.根据权利要求6所述的一种2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述脱苄基保护基反应的过程为:将中间体10溶于溶剂,并放置在-50℃以下低温环境中,搅拌至少20min,再滴加三氯化硼,并升温至-40~-30℃,搅拌1~5h。9. A kind of 2-ethylbutyl ((S)-(((2R,3R,4S,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 6 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine The synthesis method of acid compounds is characterized in that: the process of the debenzyl protecting group reaction is: dissolve the intermediate 10 in a solvent, place it in a low temperature environment below -50°C, stir for at least 20 minutes, and then add trichloride dropwise Boronize, raise the temperature to -40~-30°C, and stir for 1~5 hours. 10.根据权利要求6所述的一种2-乙基丁基((S)-(((2R,3R,4S,5R)-5-(4-氨基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基)-4-氟-3-羟基四氢呋喃-2-基)甲氧基)(苯氧基)磷酰基)-L-丙氨酸化合物的合成方法,其特征在于:所述磷酸化反应的过程为:将中间体11溶于溶剂及2-乙基丁基((S)-(全氟苯氧基)(苯氧基)磷酰基)-L-丙氨酸溶于溶剂,并放置在冰浴环境中,缓慢滴加二甲基氯化铝,升至室温搅拌5~10d。10. A kind of 2-ethylbutyl ((S)-(((2R,3R,4S,5R))-5-(4-aminopyrrolo[2,1-f][ according to claim 6 1,2,4]triazin-7-yl)-5-cyano)-4-fluoro-3-hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alanine A method for synthesizing acid compounds, characterized in that: the process of the phosphorylation reaction is: dissolving intermediate 11 in a solvent and 2-ethylbutyl ((S)-(perfluorophenoxy)(phenoxy) Phosphoryl)-L-alanine is dissolved in the solvent and placed in an ice bath environment. Dimethylaluminum chloride is slowly added dropwise, and the mixture is raised to room temperature and stirred for 5 to 10 days.
CN202310552338.7A 2023-05-17 2023-05-17 A method for synthesizing fluororemdesivir Active CN117126199B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310552338.7A CN117126199B (en) 2023-05-17 2023-05-17 A method for synthesizing fluororemdesivir

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310552338.7A CN117126199B (en) 2023-05-17 2023-05-17 A method for synthesizing fluororemdesivir

Publications (2)

Publication Number Publication Date
CN117126199A true CN117126199A (en) 2023-11-28
CN117126199B CN117126199B (en) 2024-12-06

Family

ID=88849767

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310552338.7A Active CN117126199B (en) 2023-05-17 2023-05-17 A method for synthesizing fluororemdesivir

Country Status (1)

Country Link
CN (1) CN117126199B (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153314A (en) * 2010-09-13 2013-06-12 吉里德科学公司 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
CN107073005A (en) * 2014-10-29 2017-08-18 吉利德科学公司 Methods of treating viral infections of the Filoviridae family
CN108348526A (en) * 2015-09-16 2018-07-31 吉利德科学公司 Method of treating arenaviridae and coronaviridae viral infections
CN110724174A (en) * 2019-09-10 2020-01-24 嘉兴金派特生物科技有限公司 Pyrrolotriazine compound, composition and application thereof
CN111875638A (en) * 2020-07-16 2020-11-03 江苏省原子医学研究所 Preparation method of Reidesciclovir derivative, Reidesciclovir derivative and application thereof
CN113248508A (en) * 2020-02-13 2021-08-13 安徽诺全药业有限公司 N-protected heterocycles, method for the production thereof and method for the production of C-nucleoside derivatives
CN114149434A (en) * 2020-09-08 2022-03-08 安徽诺全药业有限公司 A kind of heterocyclic compound and its preparation method and application
CN114437159A (en) * 2022-04-11 2022-05-06 佛山市晨康生物科技有限公司 Cyclic carbonate nucleoside compound and application thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153314A (en) * 2010-09-13 2013-06-12 吉里德科学公司 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
CN107073005A (en) * 2014-10-29 2017-08-18 吉利德科学公司 Methods of treating viral infections of the Filoviridae family
CN108348526A (en) * 2015-09-16 2018-07-31 吉利德科学公司 Method of treating arenaviridae and coronaviridae viral infections
CN110724174A (en) * 2019-09-10 2020-01-24 嘉兴金派特生物科技有限公司 Pyrrolotriazine compound, composition and application thereof
CN113248508A (en) * 2020-02-13 2021-08-13 安徽诺全药业有限公司 N-protected heterocycles, method for the production thereof and method for the production of C-nucleoside derivatives
CN111875638A (en) * 2020-07-16 2020-11-03 江苏省原子医学研究所 Preparation method of Reidesciclovir derivative, Reidesciclovir derivative and application thereof
CN114149434A (en) * 2020-09-08 2022-03-08 安徽诺全药业有限公司 A kind of heterocyclic compound and its preparation method and application
CN114437159A (en) * 2022-04-11 2022-05-06 佛山市晨康生物科技有限公司 Cyclic carbonate nucleoside compound and application thereof

Also Published As

Publication number Publication date
CN117126199B (en) 2024-12-06

Similar Documents

Publication Publication Date Title
HRP20000276A2 (en) Chemical compounds
EP0515071A2 (en) O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
MX2012011324A (en) Stereoselective synthesis of phosphorus containing actives.
EP0532088A1 (en) O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl macrolides
HRP20000275A2 (en) Chemical compounds
EP0536896A1 (en) Imidazolidyl macrolides having immunosuppressive activity
EP2308886B1 (en) Process for the production of a spiroketal derivative
EP3964518A1 (en) Cd73 inhibitor, preparation method therefor and application thereof
CN112513061A (en) 4' -thio-nucleotide and-nucleoside prodrugs for the treatment of cancer
RU2194511C2 (en) Application of 5-ethynyluracil as an activator of uracil-reductase, pharmaceutical composition, method for its obtaining, pharmaceutical composition for increasing the action or decreasing the toxicity of 5-fluouracil
CN117126199A (en) Synthesis method of fluoroRuidexivir
US9169257B2 (en) Crystal forms of adefovir dipivoxil and processes for preparing the same
KR20090104002A (en) Solids of macrolide compounds, preparation method thereof and pharmaceutical composition thereof
CN116675664B (en) Biological orthogonal bond-breaking reaction system, prodrug and application
WO2019080724A1 (en) Nucleoside phosphate compound and preparation method therefor and use thereof
Samanta et al. Possible anticancer agents: QSAR analogs of glutamamide: Synthesis and pharmacological activity of 1, 5-N, N′-disubstituted-2-(substituted benzenesulphonyl) glutamamides
EP0155164A2 (en) Novel cyanoimidazole nucleoside derivatives
KR20200065056A (en) Tryptolide derivatives and methods for their preparation and application
WO2021047672A1 (en) Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating nuclear receptor subfamily 4 group member 1-mediated disease
CN101880281B (en) Thiophane nucleoside analogues and preparation method and application thereof
CN106928224B (en) Indoles Sophoridine derivative and preparation method thereof
EP4089086B1 (en) Crystal form of pyrrolidinyl urea derivative and application thereof
CN110446713A (en) A kind of pyrazolidine pyrimidine derivative and its use and pharmaceutical composition
CN115260260B (en) Selenium-containing ribose compound with KGA inhibition activity and application of synthesis method thereof
CN109776571B (en) Rapamycin analogue and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant